The Danish pharmaceutical giant Novo Nordisk A/S ( NVO ) published news on Monday that its Evoke and Evoke+ phase 3 trials using oral semaglutide (Wegovy/Ozempic) as a potential treatment for Alzheimer’s Disease "did not demonstrate a statisticallyI have been investing in the stock market since I was 17 years old, and over the 25+ years since I have learned the joy of compounding, the value of dividend reinvesting, and the principle that patient investing through good times and bad brings the greatest rewar ...